Secondary Raynaud's Phenomenon

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Secondary Raynaud's Phenomenon trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 4

NCT07112183

Open Label Treprostinil Raynaud's Study

Raynaud's phenomenon is a condition where the blood vessels in participants fingers and toes get too narrow when cold or stressed. This makes participants finge…

United States30 participantsStarted 2025-10-15

Treatment: Oral treprostinil (UT-15C) sustained release tablets

All recent trials (30 shown)

CompletedPhase 3

NCT04040322

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)

This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of iloprost on the frequency of and relie…

United States198 participantsStarted 2019-10-14

Treatment: Placebo IV infusion, Iloprost Injection, for intravenous use

CompletedPhase 2

NCT03867097

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

This is a Phase 2, multicenter, double-blind, randomized, placebo-controlled study to evaluate the effect of iloprost on the symptomatic relief of Raynaud's Phe…

United States34 participantsStarted 2019-03-07

Treatment: Placebo IV infusion, Iloprost Injection, for intravenous use

Secondary Raynaud's Phenomenon

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Open Label Treprostinil Raynaud's Study

All recent trials (30 shown)

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Open Label Treprostinil Raynaud's Study

All recent trials (30 shown)

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis

A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Se…

Cold Challenge With C21 in RP

Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon

Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis

Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon

Identification of TRP Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.

PF-00489791 For The Treatment Of Raynaud's

Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon

Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud

Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to S…

Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon

Prognostic Influence of Light Rheography Measurement of Patients With Secondary Raynaud Syndrome With Ulcers on Hands

Tadalafil for the Treatment of Raynaud's

Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon

Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet

Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon

A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon